Wedbush Cuts Earnings Estimates for Revolution Medicines

Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) – Analysts at Wedbush reduced their FY2029 EPS estimates for shares of Revolution Medicines in a research note issued to investors on Thursday, September 11th. Wedbush analyst R. Driscoll now expects that the company will post earnings of $1.23 per share for the year, down from their prior […]

Leave a Reply

Your email address will not be published.

Previous post Nebius Group (NASDAQ:NBIS) Upgraded at Wall Street Zen
Next post FY2026 EPS Estimates for Planet Labs PBC Reduced by Analyst